anti-CD7 PEBL CAR-T cell therapy

This autologous chimeric antigen receptor (CAR) T-cell therapy, developed by the National University Hospital (NUH) and the National University of Singapore (NUS), targets the CD7 antigen for the treatment of relapsed or refractory T-lineage acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma. The therapy utilizes a second-generation CAR construct (anti-CD7-41BB-CD3ζ) and incorporates a novel Protein Expression Blocker (PEBL) technology. The PEBL consists of an anti-CD7 single-chain variable fragment (scFv) linked to an intracellular retention signal, which prevents the expression of CD7 on the surface of the CAR T-cells. This downregulation is critical to prevent fratricide, as CD7 is naturally expressed on T-cells, thereby allowing for the successful expansion and persistence of the therapeutic cells during production and after infusion.

Other names

anti-CD7 PEBL CAR T-cellsanti-CD-7 PEBL CAR T-cellsanti-CD 7 PEBL CAR T-cellsCD7 CAR-PEBL T-cellsCD-7 CAR-PEBL T-cellsCD 7 CAR-PEBL T-cellsanti-CD7-41BB-CD3ζ-PEBL CAR T-cellsautologous anti-CD7 CAR T-cell therapy